Anticoagulation After Ischemic Stroke
Direct Oral Anticoagulants (DOACs) Over Warfarin for Atrial Fibrillation
For patients with ischemic stroke and atrial fibrillation, use apixaban, dabigatran, edoxaban, or rivaroxaban in preference to warfarin for secondary stroke prevention. 1
- DOACs demonstrate noninferior reduction in thromboembolic risk compared to warfarin with significantly reduced bleeding complications, including intracranial hemorrhage 2
- This recommendation applies to nonvalvular AF (excluding moderate-to-severe mitral stenosis or mechanical heart valves) 1
- DOACs are preferred regardless of whether AF is paroxysmal, persistent, or permanent 1
Timing of Anticoagulation Initiation
For Transient Ischemic Attack (TIA)
Initiate anticoagulation immediately after TIA in patients with nonvalvular AF. 1
For Ischemic Stroke with Low Hemorrhagic Transformation Risk
Initiate anticoagulation between 2-14 days after stroke onset in patients at low risk for hemorrhagic conversion. 1
- Recent evidence from ELAN and TIMING trials supports earlier initiation (within 48 hours to 5 days) for minor or moderate strokes, demonstrating safety with improved functional outcomes and reduced mortality without increased bleeding 3
- Early initiation within 48 hours appears safe and beneficial for cardioembolic minor ischemic stroke 4
For Ischemic Stroke with High Hemorrhagic Transformation Risk
Delay anticoagulation beyond 14 days in patients at high risk for hemorrhagic conversion. 1
- Large infarct size is the primary factor increasing hemorrhagic transformation risk 5
- Presence of cerebral microbleeds, hemorrhage on imaging, or recent thrombolytic therapy increases bleeding risk 5
- Parenteral anticoagulation within 48 hours is associated with increased hemorrhagic transformation and should be avoided 5
Specific Agent Selection
For Nonvalvular Atrial Fibrillation
- First-line options: Apixaban, dabigatran, edoxaban, or rivaroxaban 1
- Alternative: Warfarin (target INR 2.5, range 2.0-3.0) if DOACs contraindicated 1, 6
- End-stage renal disease/dialysis: Warfarin or dose-adjusted apixaban may be reasonable 1
For Valvular Heart Disease
- Moderate-to-severe mitral stenosis or mechanical heart valves: Warfarin is required; DOACs are contraindicated 1
- Up to 20% of patients in DOAC trials had some degree of valvular heart disease (excluding the above), supporting DOAC use in mild valvular disease 1
Antiplatelet Therapy Considerations
For Non-Cardioembolic Stroke
Aspirin 160-300 mg should be initiated within 24-48 hours after stroke onset in patients not receiving anticoagulation. 7
- For patients receiving IV alteplase, delay aspirin for 24 hours 7
- Minor stroke or high-risk TIA: Dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days is beneficial for early secondary prevention up to 90 days 7
- Ticagrelor is not recommended over aspirin for acute minor stroke treatment 7
Contraindication
Do not use aspirin as a substitute for IV alteplase or mechanical thrombectomy in eligible patients. 7
Critical Contraindications and Pitfalls
Avoid Early Parenteral Anticoagulation
- Routine parenteral anticoagulation (heparin, LMWH) within 48 hours increases hemorrhagic transformation risk without proven benefit for stroke prevention 5
- Exception: Prophylactic low-dose subcutaneous heparin or LMWH for venous thromboembolism prevention in patients with restricted mobility 6
Left Atrial Appendage Closure
For patients with AF and contraindications to lifelong anticoagulation who can tolerate at least 45 days of therapy, percutaneous left atrial appendage closure with the Watchman device may be reasonable. 1
Risk Stratification Framework
Factors favoring delayed anticoagulation (>14 days):
- Large infarct size (>1.5 cm or involving significant cortical territory) 5
- Hemorrhagic transformation on imaging 5
- Recent thrombolytic therapy 5
- Cerebral microbleeds on MRI 5
- Recent surgical procedures 3
Factors supporting early anticoagulation (2-5 days):